Literature DB >> 31103348

Clinical and Prognostic Significance of the Epithelial-Mesenchymal Transition in Stage IA Lung Adenocarcinoma: A Propensity Score-Matched Analysis.

Taichi Matsubara1, Tetsuzo Tagawa2, Kazuki Takada1, Gouji Toyokawa1, Mototsugu Shimokawa3, Yuka Kozuma1, Takaki Akamine1, Akira Haro1, Atsushi Osoegawa1, Masaki Mori1.   

Abstract

BACKGROUND: The epithelial-mesenchymal transition (EMT) describes the process through which cells lose epithelial characteristics and gain a mesenchymal phenotype. The EMT contributes to tumor invasion and cancer progression, and is associated with metastasis and poor survival of patients with non-small-cell lung cancer. However, little is known about the relationships between the EMT and the clinicopathologic characteristics of patients with stage IA lung adenocarcinoma. PATIENTS AND METHODS: We conducted immunohistochemical analysis of the expression of the EMT markers E-cadherin and vimentin of specimens acquired from 183 consecutive patients with stage IA lung adenocarcinoma. The clinicopathologic significance of the association of the EMT status with E-cadherin and vimentin expression was analyzed after propensity score matching.
RESULTS: E-cadherin and vimentin were detected in 68.3% and 18.6% of stage IA lung adenocarcinomas, respectively. The presence of cells with EMT conversion was associated with older patient age. A propensity score-matched cohort (128 patients) was used for further analyses. Computed tomography revealed that tumors with EMT conversion showed solid-dominant nodules compared to those without conversion. Survival analysis after propensity score matching showed that the EMT correlated with poor disease-free survival (hazard ratio = 2.57, P = .0451) and overall survival (hazard ratio = 4.23, P = .0471). Multivariate analysis revealed that the EMT was an independent predictor of shorter disease-free survival.
CONCLUSION: The EMT was a significant predictor of poor prognosis of patients with stage IA lung adenocarcinoma. The EMT status may serve as an indicator for administering adjuvant therapy.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  E-cadherin; Early stage; Lung cancer; Prognosis; Vimentin

Mesh:

Substances:

Year:  2019        PMID: 31103348     DOI: 10.1016/j.cllc.2019.04.006

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN: 1525-7304            Impact factor:   4.785


  5 in total

1.  Cellular and Molecular Profiling of Tumor Microenvironment and Early-Stage Lung Cancer.

Authors:  Radu Pirlog; Paul Chiroi; Ioana Rusu; Ancuta Maria Jurj; Liviuta Budisan; Cecilia Pop-Bica; Cornelia Braicu; Doinita Crisan; Jean-Christophe Sabourin; Ioana Berindan-Neagoe
Journal:  Int J Mol Sci       Date:  2022-05-11       Impact factor: 6.208

2.  Increased Tumor Growth Rate and Mesenchymal Properties of NSCLC-Patient-Derived Xenograft Models during Serial Transplantation.

Authors:  José Miguel Pardo-Sánchez; Nuria Mancheño; José Cerón; Carlos Jordá; Emilio Ansotegui; Óscar Juan; Sarai Palanca; Antonio Cremades; Carolina Gandía; Rosa Farràs
Journal:  Cancers (Basel)       Date:  2021-06-14       Impact factor: 6.639

3.  Cytochalasin H isolated from mangrove-derived endophytic fungus inhibits epithelial-mesenchymal transition and cancer stemness via YAP/TAZ signaling pathway in non-small cell lung cancer cells.

Authors:  Zihan Xiu; Jiao Liu; Xin Wu; Xiangyong Li; Sanzhong Li; Xiaofeng Wu; Xiaohua Lv; Hua Ye; Xudong Tang
Journal:  J Cancer       Date:  2021-01-01       Impact factor: 4.207

Review 4.  Interleukin-11: A Potential Biomarker and Molecular Therapeutic Target in Non-Small Cell Lung Cancer.

Authors:  Jason Hongting Leung; Benjamin Ng; Wei-Wen Lim
Journal:  Cells       Date:  2022-07-21       Impact factor: 7.666

5.  Up-regulation of FAT4 enhances the chemosensitivity of colorectal cancer cells treated by 5-FU.

Authors:  Qianyuan Li; Xiukou Zhou; Zhengyu Fang; Zhiyun Pan; Huamiao Zhou
Journal:  Transl Cancer Res       Date:  2020-01       Impact factor: 1.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.